Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
Chiba University Weighs Asking University of Tokyo to Punish VART Chief Investigator
Chiba University will consider requesting the University of Tokyo to impose penalties on Issei Komuro, who is now at Japan’s most prestigious university, over a botched clinical trial he led on Novartis Pharma’s blood pressure drug Diovan (valsartan). In its…
To read the full story
Related Article
- Japan Hypertension Society to Retract Diovan Paper on VART Study
August 16, 2016
- Chiba Univ. Finds Dropout Rates of 60-80% in Secondary Endpoints, Raps VART Study as “Absolutely Unreliable”
July 16, 2014
- Chiba Univ. Advises Authors to Withdraw VART Papers
May 26, 2014
- Claims of Superior Cardiorenal Protective Effects of Diovan “Cannot Be Supported”: Outside Investigation of VART Study
April 30, 2014
- Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
ACADEMIA
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
- Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
- Real-World Study Backs Lecanemab Safety, 90% Stay on Treatment
March 25, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…